^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
vadacabtagene leraleucel (JCAR015)
i
Other names: JCAR015, anti-CD19-CD28-zeta modified CAR CD3+ T lymphocyte therapy, 19-28z T cells, Autologous T cells genetically targeted to the B cell specific antigen CD19
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BMS, Memorial Sloan-Kettering Cancer Center
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
